Sun Pharma and Moebius Medical present Phase 2b study on MM-II

There is an urgent need for more therapeutic treatment options for patients with painful osteoarthritis

Moderna announces positive Phase 3 efficacy data for next generation COVID-19 vaccine

Higher efficacy was observed in mRNA-1283 compared to Spikevax in adults 18 years of age and older

AxoSim appoints Alif Saleh as CEO

Co-founder and previous CEO Lowry Curley becomes Chief Scientific Officer

IOL Chemicals receives EDQM CEP certificate for Pantoprazole Sodium Sesquihydrate and Allopurinol

EDQM has also issued a Certificate of Suitability for Allopurino

Syntegon acquires Telstar

Innovative technologies and comprehensive services to strengthen Syntegon’s strategic growth

Merck Specialities’ unique initiative to raise bladder cancer awareness

Modular ATP study of the mCRM System meets primary safety and efficacy endpoints

Additional data from APPRAISE ATP trial reinforce modular therapy approach

Biocon posts Q4 FY24 PAT at Rs. 135 Cr

EBITDA for the quarter stood at Rs 964 crore, representing an EBITDA margin of 24%

Merck announces positive data for investigational, 21-Valent pneumococcal conjugate vaccine

Late-breaker Phase 3 STRIDE-10 trial presented as an oral presentation at European Society of Clinical Microbiology and Infectious Diseases

AstraZeneca’s Truqap plus Faslodex recommended for approval in the EU by CHMP for cancer treatment

Recommendation based on CAPItello-291 results which showed the Truqap combination reduced the risk of disease progression or death by 50%